gene therapy

Caught Their Interest

Business Insider writes that pharmaceutical companies' interest in gene therapies has been piqued.

Quickly, Quickly

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Advances in gene therapy and other fields could aid in protecting astronauts from the effects of radiation, the Guardian says.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

Technology Review reports that animals given large gene therapies doses have suffered fatal side effects.

Real and Pricey

Pacific Standard notes that gene therapy has become more of a reality, but with a high price tag.

Miles to Go

Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.

Bit High

A nonprofit group argues that Spark Therapeutics' Luxturna is too expensive, Forbes reports.

Diabetes Respite

University of Pittsburgh-led team finds that gene therapy could treat mice with type 1 diabetes for a few months, the Los Angeles Times reports.


Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.